Skip to main content

Catalio Capital Management — Portfolio, Page 5

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

132
Companies
$12.7B
Total invested
$93.1M
Avg. check
21
Industries
Biotechnology 19Medical 11Health Care 10Pharmaceutical 8Therapeutics 8Life Science 8+15 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 97120 of 132
Enveda Biosciences
September 2025

Enveda Biosciences is a biotechnology company that develops novel medications derived from plants.

Biotechnology · Boulder$150.0M Series D
OSPRI
August 2025

OSPRI is updating the infectious illness testing plan.

Biotechnology · Mckinney$30.0M Series Unknown
Amalgam Rx
August 2025

Amalgam Rx develops and distributes digital health products that support patients and healthcare providers in decision-making.

CRM · Wilmington$7.9M Series Unknown
Superluminal Medicines
August 2025

Superluminal Medicines is a generative biological and chemical company that innovates drug discovery and development processes.

Biotechnology · BostonCorporate Round
ArriVent
July 2025

ArriVent develops pharmaceutical products to cure presently untreatable cancer.

Biotechnology · Pennsylvania Furnace$75.0M Post Ipo Equity
Visby Medical
June 2025

Visby Medical is a diagnostics company that develops polymerase chain reaction diagnostic tests for the detection of infectious diseases.

Health Care · San Jose$55.0M Series Unknown
Syndeio Biosciences
May 2025

Syndeio Biosciences is a newly launched biotech company pioneering precision neurotherapeutics.

Biotechnology · Indianapolis$90.0M Series Unknown
GlycoEra
May 2025

GlycoEra is a biotechnology research company that produces extracellular protein degraders for the treatment of autoimmune diseases.

Biotechnology · Schlieren$130.0M Series B
Xilis
April 2025

Xilis is an oncology and precision health company that provides technologies to diagnoses cancer.

Biotechnology · Durham$19.4M Series Unknown
Perceive Pharma
February 2025

Perceive Pharma operates as a pharmaceutical company.

Life Science · San Francisco$15.0M Series A
DNA Script
February 2025

DNA Script is a disruptive DNA synthesis company harnessing biology to accelerate breakthroughs in life science and human health.

Biotechnology · Le Kremlin-bicêtre$4.7M Grant
PinkDx
January 2025

PinkDx is a biotechnology company.

Biopharma · Indianapolis$5.0M Series A
Medical Informatics
January 2025

Medical Informatics offers solutions that give care teams access to the data they need to take action for alarm management and safety.

Health Care · Houston$5.0M Debt Financing
Alentis Therapeutics
November 2024

ALENTIS Therapeutics is a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer.

Biotechnology · Allschwil$181.4M Series D
Orasis Pharmaceuticals
October 2024

Orasis Pharmaceuticals is an ophthalmic pharmaceutical company that develops eye drops for the treatment of presbyopia.

Clinical Trials · Ponte Vedra$68.0M Series D
Noetik
September 2024

Noetik is an AI-native biotechnology company that applies machine learning to large-scale human multimodal spatial omics datasets.

Artificial Intelligence (AI) · South San Francisco$1.0M Grant
EGenesis
September 2024

EGenesis is a gene editing and genome engineering company developing human-compatible engineered organs to treat diseases.

Biopharma · Cambridge$191.0M Series D
Elektrofi
August 2024

Elektrofi develops hyper concentration microparticle technology for subcutaneous biologic medicine delivery.

Alternative Medicine · Boston$112.3M Series C
Recursion Pharmaceuticals
June 2024

Recursion Pharmaceuticals is a biotech company that develops a drug discovery platform and pipeline with machine learning.

Artificial Intelligence (AI) · Salt Lake City$200.0M Post Ipo Equity
Neumora Therapeutics
April 2024

Neumora Therapeutics operates as a clinical-stage biotechnology company.

Biotechnology · Watertown$2.6M Grant
Clasp Therapeutics
March 2024

Clasp Therapeutics offers to reach of immuno-oncology with novel precision medicines that enable the immune system.

Biotechnology · Cambridge$150.0M Series A
NextPoint Therapeutics
February 2024

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients.

Biotechnology · Cambridge$42.5M Series B
Lassen Therapeutics
December 2023

Lassen Therapeutics develops antibody biotherapeutics to help improve the lives of patients suffering from serious diseases.

Biotechnology · San Diego$85.0M Series B
Centenara Labs
September 2023

Centenara Labs is an integrated biotechnology platform company that invests in people and ideas to develop therapies.

Biotechnology · SchlierenDebt Financing

Where Catalio Capital Management invests

Biotechnology19
Medical11
Health Care10
Pharmaceutical8
Therapeutics8
Life Science8

About Catalio Capital Management's portfolio

How many companies has Catalio Capital Management invested in?

Catalio Capital Management has invested in 132 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Catalio Capital Management invest in?

Catalio Capital Management's top investment sectors include Biotechnology, Medical, Health Care, Pharmaceutical, Therapeutics. The firm invests across 21 different industry categories.

What is Catalio Capital Management's largest investment?

Among tracked funding rounds, Recursion Pharmaceuticals received $200.0M in a Post Ipo Equity round. Catalio Capital Management's total known invested capital is $12.7B.

What is the average investment size for Catalio Capital Management?

Catalio Capital Management's average investment size is $93.1M across its portfolio of 132 companies.

What are Catalio Capital Management's most recent investments?

Recent Catalio Capital Management portfolio additions include Enveda Biosciences, OSPRI, Amalgam Rx, Superluminal Medicines, ArriVent. These companies were founded in 2020 or later.

Reach the founders behind these 132 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →